Keryx Biopharmaceuticals has reported its earnings a month ago and the market is still waiting for its latest reports especially that their shares have been declining at 2.7% within the period since their last announcement.
Today, we are about to scrutinize the latest about Keryx and see their progress and areas which they need to focus on.
Narrower Loss in Quarter 1
Zacks Consensus has estimated 19 cents loss for Keryx but it came out a lot narrower with an actual loss of 18 cents per share during the first quarter of this year. Its revenues hit $21.8 million instead of the $21.7 million predictions of Zacks and a lot higher to the $11.8 million earnings of the previous year.
Keryx launched Auryxia for individuals with chronic kidney diseases and its high demand during the first quarter after being launched last year during the fourth quarter has really been overwhelming as it reaches $20.6 million net product sales in the US alone. This figure is 96% higher compared to $10.5 million in sales in the prior year.
In addition, Keryx also earns license revenues on Riona’s sales. Riona is Japanese’ trade name for Auryxia and it has delivered a $1.1 million earnings for this quarter although it is down 15.4% compared to last year.
As to Keryx’ expenses, research and development hit $8.4 million for this quarter which is notably higher compared to the $6.8 million expenses a year ago. Selling and general, as well as administrative expenses, is up by 11.7% as it hit $25.8 million.
Estimate Movements
Fresh estimates have been showing an upward trend.
VGM Scores
Keryx has a current Growth Score of C but its momentum is a lot more promising with a grade of A. However, the stock is at F on the value side which makes it be one of the bottom stocks when it comes to investment strategy.
In general, it has an Aggregate VGM score of D and this is one of the stocks which most people would prefer if not focused on one strategy.
It currently holds the #3 rank in Zacks which makes it suitable for holding. However, we expect to see progress from this stock in the coming years.
This article was written by @valerie15 and edited by @flashfiction. This article can be found on PROFITRIBES.
Do you want to make REAL money writing?
- Writers earn 50% of the SBD payout of all cryptocurrency/finance posts they submit. Send all submissions to [email protected].
Join the Discord Channel: https://discord.gg/56Pnrwc
Omniloquent was brought to you by @yallapapi.
Recommended reading:
#1 Blockchain Simplified: https://steemit.com/crypto/@omniloquent/why-is-the-blockchain-important
#2 Real Estate Investing: https://steemit.com/busy/@omniloquent/investinginrealestate-6ti7vr2lrq
#3 Economies of Scale: https://steemit.com/business/@omniloquent/economiesofscale-ldbp306oun